Skip to main content
Fig. 5 | Cancer Communications

Fig. 5

From: Epidermal growth factor receptor (EGFR) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy: a prospective observational study

Fig. 5

Survival curves of patients with different failure sites. a Survival curves categorized by failure site. b Survival curves of T790M+ and T790M− CF patients. c Survival curves of T790M+ and T790M− BF patients. d Survival curves of T790M+ and T790M− OF patients. CF, progressive disease limited to the chest in lung/pleural tissues and lymph nodes, with no evidence of progression beyond the chest; BF, progressive disease in a previously existing site or a new site of metastatic disease in the brain, with no evidence of extracranial progression; OF, progressive disease in other distant sites or multiple sites including the chest and intracranial region. T790M mutation was detected by ddPCR. MST median survival time, ARMS amplification refractory mutation system, ddPCR droplet digital PCR

Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us